A new hope for Covid-19 treatment

Gosselies, Belgium, September 24th 2020 - Delphi Genetics announces today that it has obtained highly promising results with its Gene Therapy-based Covid-19 therapeutic candidate in in-vitro experiments.

With solid expertise in DNA development and production, Delphi Genetics has developed an innovative approach to treat patients infected by Covid-19.

The principle consists in inactivating and destroying the virus in cells where the virus is present. The main objective of this therapy is to cure the disease once patients get infected.

The company has three potential candidates, all three being tested with the collaboration of ULiège laboratories and showing promising results on human cells, with the lead candidate being able to 100% inhibit the virus, “far beyond expectations” says Cédric Szpirer, Founder and Executive Director, who leads the project.

Delphi Genetics core activity is to support its Customers in their Gene Therapy development with its CDMO solutions and services, which includes plasmid DNA production for clinical activities. “Developing a therapeutic indeed differs from our core business and has been motivated by the Global situation,” says Cédric Szpirer. “The company objective is and will remain services to drug developers”.

The next step for Delphi Genetics Covid-19 therapeutic is now to be evaluated in Clinic, with the support of partners that still need to be identified. “We have contacts with some big pharma companies but up to now, all doors are still opened,” says François Blondel, President of the Board & CEO.